Aducanumab, or BIIB037, is a monoclonal IgG1 antibody that targets extracellular amyloid-? plaques in the brain; similar to [gantenerumab], [bapineuzumab] and [solanezumab].[A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow…

Bapineuzumab has been investigated for the treatment of Alzheimer's Disease.

Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (A?) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD patho…